<DOC>
	<DOCNO>NCT01767974</DOCNO>
	<brief_summary>Using DNA acquire tumor tissue , sequence PNA-clamping EGFR gene perform . The detection rate EGFR mutation compare use paired sample .</brief_summary>
	<brief_title>Comparison Sequencing PNA Clamping EGFR Gene Patients With Non-Small Cell Type Lung Cancer</brief_title>
	<detailed_description>Single arm , open label , prospective , observational study gefitinib treatment locally advance ( stage IIIB ) IV ( metastatic ) relapse NSCLC patient . Using DNA acquire tumor tissue , sequence PNA-clamping EGFR gene perform . The detection rate EGFR mutation compare use paired sample .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Locally advanced stage IIIB suitable curative therapy stage IV ( metastatic ) disease relapse NSCLC ECOG Performance status 0~2 . Written Informed Consent Female male patient age 18 year , eligible treatment NSCLC Previous exposure EGFRTKI Concomitant use anticancer drug EGFRTKI Patients without available Tumor DNA As judged investigator , evidence severe uncontrolled systemic disease ( e.g . unstable uncompensated respiratory , cardiac , hepatic , renal disease ) Evidence significant clinical disorder laboratory find make undesirable subject participate study Pregnancy breastfeed woman ( woman childÂ¬bearing potential ) . Women childbearing potential must practice acceptable method birth control prevent pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Non-Small Cell lung cancer</keyword>
</DOC>